Cargando…
Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed...
Autores principales: | Moga, Silvia, Teodorescu, Andreea, Ifteni, Petru, Petric, Paula-Simina, Miron, Ana-Aliana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081886/ https://www.ncbi.nlm.nih.gov/pubmed/35547265 http://dx.doi.org/10.2147/NDT.S361405 |
Ejemplares similares
-
Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga, Silvia, et al.
Publicado: (2021) -
Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
por: Miron, Ana Aliana, et al.
Publicado: (2023) -
Clozapine Efficacy in a Case of Severe Treatment-Resistant Postpartum Psychosis
por: Teodorescu, Andreea, et al.
Publicado: (2021) -
Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study
por: Miron, Ana-Aliana, et al.
Publicado: (2022) -
Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)